Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PPIA | P62937 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825896 | 0.87 | MAPK8 (0.45) | L3MBTL1LMNATDP1ALDH1A1POLB | |
| SCHEMBL4828094 | 0.83 | L3MBTL1 (0.55) | L3MBTL1KMT2AMAPK1LMNAHTT | |
| SCHEMBL17595922 | 0.81 | L3MBTL1 (0.58) | L3MBTL1KMT2AHTTALDH1A1POLB | |
| SCHEMBL20831533 | 0.78 | TDP1 (0.72) | L3MBTL1MAPK1LMNAHTTTDP1 | |
| SCHEMBL5359763 | 0.75 | MAPK8 (0.54) | KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL6850742 | 0.74 | MAPK8 (0.56) | KMT2ALMNAHPGDMAPTSMN1; SMN2 | |
| SCHEMBL5405986 | 0.74 | MAPK8 (0.55) | LMNAHPGDSMN1; SMN2 | |
| SCHEMBL1313733 | 0.73 | L3MBTL1 (0.74) | L3MBTL1KMT2AMAPK1LMNAHTT | |
| SCHEMBL4828049 | 0.73 | L3MBTL1 (0.49) | L3MBTL1MAPK1LMNAHTTTDP1 | |
| SCHEMBL7682228 | 0.72 | L3MBTL1 (0.52) | L3MBTL1KMT2AMAPK1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1373258-B1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1252158-B1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1229034-B1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | PFIZER PROD INC (US) | 2005-04-13 | — | — | EP | disclosed |
| US-20050049258-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| US-6828333-B2 | Treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040171798-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC | 2004-09-02 | — | — | US | disclosed |
| EP-1373258-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2003-02-06 | — | — | US | disclosed |
| EP-1252158-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002060896-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-1229034-A1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | Pfizer Products Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001057036-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | L3MBTL1 3318/4885KMT2A 2541/4885MAPK1 2157/4885 |
| US-20050049258-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PDE4A, PDE4B, PDE3B | L3MBTL1 3323/4885KMT2A 1819/4885MAPK1 1568/4885 |
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PDE4B, PDE4A, NOX4 | L3MBTL1 4587/4885KMT2A 3613/4885MAPK1 485/4885 |
| US-20040171798-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | NOX3, PDE4A, NOX1 | L3MBTL1 3467/4885KMT2A 3049/4885MAPK1 2059/4885 |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | CBR1, PDE4A, PDE4B | L3MBTL1 2643/4885KMT2A 3432/4885MAPK1 2003/4885 |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | NOX3, NOX1, NOX4 | L3MBTL1 3449/4885KMT2A 3442/4885MAPK1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.